Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Molecular Targeted Therapy"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 19069
Tytuł:
FOXO3 is a potential biomarker and therapeutic target for premature ovarian insufficiency (Review).
Autorzy:
Meng X; Institute of Clinical Anatomy and Reproductive Medicine, Hengyang Medical College, South China University, Hengyang, Hunan 421001, P.R. China.
Peng L; Institute of Clinical Anatomy and Reproductive Medicine, Hengyang Medical College, South China University, Hengyang, Hunan 421001, P.R. China.
Wei X; Heart Research Institute, Hengyang Medical College, South China University, Hengyang, Hunan 421001, P.R. China.
Li S; Institute of Clinical Anatomy and Reproductive Medicine, Hengyang Medical College, South China University, Hengyang, Hunan 421001, P.R. China.
Pokaż więcej
Źródło:
Molecular medicine reports [Mol Med Rep] 2023 Feb; Vol. 27 (2). Date of Electronic Publication: 2022 Dec 23.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Forkhead Box Protein O3*/genetics
Forkhead Box Protein O3*/metabolism
Primary Ovarian Insufficiency*/diagnosis
Primary Ovarian Insufficiency*/therapy
Molecular Targeted Therapy*
Female ; Humans ; Aging ; Inflammation/complications ; Insulin/metabolism ; Infertility, Female/etiology ; Biomarkers/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Autorzy:
Talia KL; Royal Children's Hospital, Royal Women's Hospital and Australian Centre for the Prevention of Cervical Cancer, Melbourne, Vic, Australia. Electronic address: .
Banet N; Department of Pathology, The Cleveland Clinic, Cleveland, USA.
Buza N; Department of Pathology, Yale University School of Medicine, New Haven, USA.
Pokaż więcej
Źródło:
Pathology [Pathology] 2023 Feb; Vol. 55 (1), pp. 8-18. Date of Electronic Publication: 2022 Nov 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Biomarkers, Tumor*/metabolism
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/therapy
Receptor, ErbB-2*/metabolism
Adenocarcinoma, Mucinous*/drug therapy
Adenocarcinoma, Mucinous*/metabolism
Molecular Targeted Therapy*
Female ; Humans
Czasopismo naukowe
Szczegóły
Tytuł:
Pharos 2023: an integrated resource for the understudied human proteome.
Autorzy:
Kelleher KJ; National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Sheils TK; National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Mathias SL; Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Yang JJ; Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Metzger VT; Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Siramshetty VB; National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Nguyen DT; National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Jensen LJ; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen 2200, Copenhagen, Denmark.
Vidović D; Institute for Data Science and Computing, University of Miami, Coral Gables, FL 33146, USA.; Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Schürer SC; Institute for Data Science and Computing, University of Miami, Coral Gables, FL 33146, USA.; Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Holmes J; Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Sharma KR; National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Pillai A; National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Bologa CG; Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Edwards JS; Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.; Department of Chemistry and Chemical Biology, University of New Mexico, Albuquerque, NM 87131, USA.
Mathé EA; National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Oprea TI; Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Pokaż więcej
Źródło:
Nucleic acids research [Nucleic Acids Res] 2023 Jan 06; Vol. 51 (D1), pp. D1405-D1416.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Databases, Factual*
Proteome*/drug effects
Molecular Targeted Therapy*
Humans ; Biological Products ; Drug Discovery ; Internet
Czasopismo naukowe
Szczegóły
Tytuł:
Rapid progress in molecular targeted therapy for allergic diseases.
Autorzy:
Nagase H; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8606, Japan. Electronic address: .
Pokaż więcej
Źródło:
Allergology international : official journal of the Japanese Society of Allergology [Allergol Int] 2023 Jan; Vol. 72 (1), pp. 1-2.
Typ publikacji:
Editorial
MeSH Terms:
Molecular Targeted Therapy*
Hypersensitivity*/drug therapy
Humans
Opinia redakcyjna
Szczegóły
Tytuł:
Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
Autorzy:
Fu S; Department of Neurology, Joint Research Institution of Altitude Health, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Zheng Q; Department of Neurology, Joint Research Institution of Altitude Health, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Zhang D; Department of Neurology, Joint Research Institution of Altitude Health, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Lin C; Department of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Ouyang L; Department of Neurology, Joint Research Institution of Altitude Health, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Zhang J; Department of Neurology, Joint Research Institution of Altitude Health, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. Electronic address: .
Chen L; Department of Neurology, Joint Research Institution of Altitude Health, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. Electronic address: leilei_.
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2022 Dec 15; Vol. 244, pp. 114842. Date of Electronic Publication: 2022 Oct 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Enzyme Inhibitors*/chemistry
Enzyme Inhibitors*/pharmacology
Enzyme Inhibitors*/therapeutic use
Neoplasms*/drug therapy
Neoplasms*/enzymology
Protein-Arginine N-Methyltransferases*/antagonists & inhibitors
Molecular Targeted Therapy*
Humans ; Arginine/metabolism ; Chemistry, Pharmaceutical
Czasopismo naukowe
Szczegóły
Tytuł:
Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer.
Autorzy:
Altıntop MD; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey. Electronic address: .
Özdemir A; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey.
Temel HE; Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey.
Demir Cevizlidere B; Cellular Therapy and Stem Cell Production, Application and Research Center (ESTEM), Eskişehir Osmangazi University, 26480, Eskişehir, Turkey; Department of Stem Cell, Institute of Health Sciences, Eskisehir Osmangazi University, 26480, Eskişehir, Turkey.
Sever B; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey.
Kaplancıklı ZA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey.
Akalın Çiftçi G; Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey; Graduate School of Health Sciences, Anadolu University, 26470, Eskişehir, Turkey.
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2022 Dec 15; Vol. 244, pp. 114851. Date of Electronic Publication: 2022 Oct 14.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Indans*/chemistry
Indans*/pharmacology
Indans*/therapeutic use
Lung Neoplasms*/drug therapy
Prostatic Neoplasms*/drug therapy
Drug Design*
Molecular Targeted Therapy*
Humans ; Male ; Apoptosis/drug effects ; Calcium ; Cell Line, Tumor ; Cell Proliferation ; Cisplatin/pharmacology
Czasopismo naukowe
Szczegóły
Tytuł:
Nanoparticles for super-resolution microscopy: intracellular delivery and molecular targeting.
Autorzy:
Pramanik SK; CSIR - Central Salt and Marine Chemicals Research Institute, Gijubhai Badheka Marg, Bhavnagar, Gujarat 364002, India. .
Sreedharan S; Human Science Research Centre, University of Derby, Kedleston road, DE22 1GB, UK.
Tiwari R; CSIR - Central Salt and Marine Chemicals Research Institute, Gijubhai Badheka Marg, Bhavnagar, Gujarat 364002, India. .
Dutta S; Department of Chemical Sciences and Centre for Advanced Functional Materials, Indian Institute of Science Education and Research, Kolkata, West Bengal, India. .
Kandoth N; Department of Chemical Sciences and Centre for Advanced Functional Materials, Indian Institute of Science Education and Research, Kolkata, West Bengal, India. .
Barman S; Department of Chemical Sciences and Centre for Advanced Functional Materials, Indian Institute of Science Education and Research, Kolkata, West Bengal, India. .
Aderinto SO; Department of Chemistry, University of Sheffield, Western Bank, Sheffield, S3 7HF, UK. .
Chattopadhyay S; Department of Biological Sciences, BITS-Pilani, K K Birla Goa Campus, NH 17B, Zuarinagar, Goa 403726, India. .
Das A; Department of Chemical Sciences and Centre for Advanced Functional Materials, Indian Institute of Science Education and Research, Kolkata, West Bengal, India. .
Thomas JA; Department of Chemistry, University of Sheffield, Western Bank, Sheffield, S3 7HF, UK. .
Pokaż więcej
Źródło:
Chemical Society reviews [Chem Soc Rev] 2022 Dec 12; Vol. 51 (24), pp. 9882-9916. Date of Electronic Publication: 2022 Dec 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Molecular Targeted Therapy*
Nanoparticles*
Microscopy, Fluorescence/methods
Czasopismo naukowe
Szczegóły
Tytuł:
Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy.
Autorzy:
Hawash M; Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus P.O. Box 7, Palestine.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2022 Dec 10; Vol. 12 (12). Date of Electronic Publication: 2022 Dec 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Antineoplastic Agents*/chemistry
Colchicine*/chemistry
Colchicine*/pharmacology
Neoplasms*/drug therapy
Tubulin*/metabolism
Molecular Targeted Therapy*
Humans ; Binding Sites ; Cell Line, Tumor ; Cell Proliferation ; Microtubules/metabolism ; Tubulin Modulators/pharmacology ; Tubulin Modulators/therapeutic use ; Tubulin Modulators/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Monitoring drug-target interactions through target engagement-mediated amplification on arrays and in situ.
Autorzy:
Al-Amin RA; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Johansson L; Department of Medical Biochemistry and Biophysics, Chemical Biology Consortium Sweden (CBCS), Science for Life Laboratory, Karolinska Institutet, Solna, Sweden.
Abdurakhmanov E; Department of Chemistry-BMC, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Landegren N; Center for Molecular Medicine, Department of Medicine (Solna), Science for Life Laboratory, Karolinska Institutet, Solna, Sweden.; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Löf L; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Arngården L; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Blokzijl A; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Svensson R; Department of Pharmacy, Uppsala University Drug Optimization and Pharmaceutical Profiling (UDOPP), Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Hammond M; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Lönn P; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Haybaeck J; Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Kamali-Moghaddam M; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Jensen AJ; Department of Medical Biochemistry and Biophysics, Chemical Biology Consortium Sweden (CBCS), Science for Life Laboratory, Karolinska Institutet, Solna, Sweden.
Danielson UH; Department of Chemistry-BMC, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Artursson P; Department of Pharmacy, Uppsala University Drug Optimization and Pharmaceutical Profiling (UDOPP), Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Lundbäck T; Department of Medical Biochemistry and Biophysics, Chemical Biology Consortium Sweden (CBCS), Science for Life Laboratory, Karolinska Institutet, Solna, Sweden.
Landegren U; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
Nucleic acids research [Nucleic Acids Res] 2022 Dec 09; Vol. 50 (22), pp. e129.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Molecular Targeted Therapy*/methods
Dasatinib/pharmacology ; Oligonucleotide Probes ; Protein Array Analysis ; Proteins ; Gefitinib/pharmacology ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Szczegóły
Tytuł:
Small Molecular Inhibitors Reverse Cancer Metastasis by Blockading Oncogenic PITPNM3.
Autorzy:
Liu Z; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Department of Breast and Thyroid Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, P. R. China.
Shi Y; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Lv L; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, P. R. China.
Chen J; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Jiang W; Cardiff China Medical Research Collaborative, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Li J; Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, P. R. China.
Lin Q; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Fang X; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Gao J; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Liu Y; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Liu Q; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Xu X; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Song E; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Gong C; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
Pokaż więcej
Źródło:
Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2022 Dec; Vol. 9 (35), pp. e2204649. Date of Electronic Publication: 2022 Oct 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Calcium-Binding Proteins*/antagonists & inhibitors
Membrane Proteins*/antagonists & inhibitors
Molecular Targeted Therapy*
Nanoparticle Drug Delivery System*
Animals ; Female ; Humans ; Mice ; Neoplasm Metastasis ; Signal Transduction ; Xenograft Model Antitumor Assays ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology
Czasopismo naukowe
Szczegóły
Tytuł:
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Autorzy:
Devos T; Department of Hematology, University Hospitals Leuven (UZ Leuven) and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), Catholic University Leuven (KU Leuven), Leuven, Belgium.
Selleslag D; Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges, Belgium.
Granacher N; Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.
Havelange V; Department of Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Benghiat FS; Department of Hemato-Oncology, Erasme Hospital, Brussels, Belgium.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 23-31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Molecular Targeted Therapy*/methods
Janus Kinase Inhibitors/*therapeutic use
Nitriles/*therapeutic use
Primary Myelofibrosis/*drug therapy
Pyrazoles/*therapeutic use
Pyrimidines/*therapeutic use
Biomarkers ; Clinical Decision-Making ; Combined Modality Therapy/methods ; Disease Management ; Disease Susceptibility ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/therapy ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Janus Kinase Inhibitors/administration & dosage ; Janus Kinase Inhibitors/adverse effects ; Nitriles/administration & dosage ; Nitriles/adverse effects ; Platelet Count ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/etiology ; Prognosis ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
[Radiation therapy and targeted therapies: Risks and opportunities].
Autorzy:
Nicolas E; Département de radiothérapie et oncologie, hôpital Pitié-Salpêtrière Charles-Foix, APHP, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: .
Lucia F; Département de radiothérapie, centre hospitalier universitaire de Brest, 2, avenue Foch, 29200 Brest, France.
Pokaż więcej
Transliterated Title:
Radiothérapie et thérapies ciblées : risques et opportunités.
Źródło:
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Oct; Vol. 26 (6-7), pp. 973-978. Date of Electronic Publication: 2022 Aug 31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Molecular Targeted Therapy*/adverse effects
Radiotherapy*/adverse effects
Ado-Trastuzumab Emtansine ; Cetuximab/therapeutic use ; Crizotinib/therapeutic use ; ErbB Receptors ; Erlotinib Hydrochloride/therapeutic use ; Gefitinib ; Humans ; Lapatinib ; Mitogen-Activated Protein Kinase Kinases ; Panitumumab ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins B-raf ; Receptor Protein-Tyrosine Kinases ; Trastuzumab
Czasopismo naukowe
Szczegóły
Tytuł:
Cancer drugs are closing in on some of the deadliest mutations.
Autorzy:
Ledford H
Pokaż więcej
Źródło:
Nature [Nature] 2022 Oct; Vol. 610 (7933), pp. 620-622.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Mutation*
Neoplasms*/drug therapy
Neoplasms*/genetics
Neoplasms*/mortality
Molecular Targeted Therapy*/methods
Molecular Targeted Therapy*/trends
Czasopismo naukowe
Szczegóły
Tytuł:
Noncoding RNAs Are Promising Therapeutic Targets for Diabetic Retinopathy: An Updated Review (2017-2022).
Autorzy:
Wang M; Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing 100193, China.; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China.; NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100193, China.
Li Q; Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing 100193, China.; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China.; NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100193, China.
Jin M; Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing 100193, China.; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China.; NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100193, China.
Wang Z; Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing 100193, China.; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China.; NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100193, China.
Zhang X; Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing 100193, China.; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China.; NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100193, China.
Sun X; Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing 100193, China.; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China.; NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100193, China.
Luo Y; Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing 100193, China.; Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China.; NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100193, China.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2022 Nov 28; Vol. 12 (12). Date of Electronic Publication: 2022 Nov 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Diabetic Retinopathy*/drug therapy
Diabetic Retinopathy*/genetics
RNA, Untranslated*/genetics
RNA, Untranslated*/metabolism
Molecular Targeted Therapy*
Adult ; Humans ; Endothelial Cells/metabolism ; MicroRNAs/genetics ; MicroRNAs/metabolism ; RNA, Circular/genetics ; RNA, Circular/metabolism ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism
SCR Disease Name:
Retinal Nonattachment, Nonsyndromic Congenital
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
Autorzy:
Krzyżanowska N; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Krawczyk P; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Wojas-Krawczyk K; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Kucharczyk T; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Milanowski J; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Pokaż więcej
Źródło:
Cells [Cells] 2022 Oct 18; Vol. 11 (20). Date of Electronic Publication: 2022 Oct 18.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/therapy
Immunotherapy*/methods
Lung Neoplasms*/therapy
Molecular Targeted Therapy*
Female ; Humans ; Male ; Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen/genetics ; Immune Checkpoint Inhibitors ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In vivo visualization and molecular targeting of the cardiac conduction system.
Autorzy:
Goodyer WR; Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.; Department of Pediatrics, Stanford University, Stanford, California, USA.
Beyersdorf BM; Department of Cardiovascular Surgery, Institute Insure (Institute for Translational Cardiac Surgery), German Heart Center Munich, Technische Universität München, Munich, Germany.
Duan L; Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.
van den Berg NS; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.
Mantri S; Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.
Galdos FX; Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.
Puluca N; Department of Cardiovascular Surgery, Institute Insure (Institute for Translational Cardiac Surgery), German Heart Center Munich, Technische Universität München, Munich, Germany.
Buikema JW; Department of Cardiology, Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.; Department of Cardiology, Amsterdam University Medical Center, Location VUmc, Amsterdam, Netherlands.
Lee S; Department of Pharmacy, Bioconvergence Program, Sungkyunkwan University, Suwon, South Korea.
Salmi D; Department of Pathology and.
Robinson ER; Department of Radiology, Stanford University, Stanford, California, USA.
Rogalla S; Division of Gastroenterology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Cogan DP; Departments of Chemistry and Chemical Engineering and Sarafan ChEM-H Institute, Stanford University, Stanford, California, USA.
Khosla C; Departments of Chemistry and Chemical Engineering and Sarafan ChEM-H Institute, Stanford University, Stanford, California, USA.
Rosenthal EL; Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Wu SM; Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.; Department of Pediatrics, Stanford University, Stanford, California, USA.; Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Pokaż więcej
Źródło:
The Journal of clinical investigation [J Clin Invest] 2022 Oct 17; Vol. 132 (20). Date of Electronic Publication: 2022 Oct 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Heart Conduction System*/metabolism
Molecular Targeted Therapy*
Animals ; Arrhythmias, Cardiac/genetics ; Arrhythmias, Cardiac/metabolism ; Heart/physiology ; Humans ; Mice ; Myocardium
Czasopismo naukowe
Szczegóły
Tytuł:
Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
Autorzy:
Su L; Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Chen X; Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Zhang J; Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Gao J; Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Yan F; Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Pokaż więcej
Źródło:
Biometrical journal. Biometrische Zeitschrift [Biom J] 2022 Oct; Vol. 64 (7), pp. 1192-1206. Date of Electronic Publication: 2022 May 17.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Molecular Targeted Therapy*
Research Design*
Bayes Theorem ; Biomarkers ; Computer Simulation ; Humans ; Random Allocation
Czasopismo naukowe
Szczegóły
Tytuł:
Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.
Autorzy:
Luger AL; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. .; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany. .; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. .; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. .
König S; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Samp PF; Department of Neuroradiology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Urban H; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Divé I; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Burger MC; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Voss M; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Franz K; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; Department of Neurosurgery, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Fokas E; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; Department of Radiotherapy and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Filipski K; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; Neurological Institute (Edinger Institute), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Demes MC; Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Centers for Personalized Medicine (ZPM), Heidelberg Site, Heidelberg, Germany.
Sahm F; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Neuropathology, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.
Reuss DE; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Neuropathology, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.
Harter PN; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; Neurological Institute (Edinger Institute), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wagner S; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Hattingen E; Department of Neuroradiology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Wichert J; Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Lapa C; Faculty of Medicine, Nuclear Medicine, University of Augsburg, Augsburg, Germany.; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Fröhling S; German Cancer Consortium (DKTK), Heidelberg, Germany.; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Steinbach JP; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Ronellenfitsch MW; Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Pokaż więcej
Źródło:
Journal of neuro-oncology [J Neurooncol] 2022 Sep; Vol. 159 (2), pp. 243-259. Date of Electronic Publication: 2022 Jul 21.
Typ publikacji:
Journal Article
MeSH Terms:
Brain Neoplasms*
Molecular Targeted Therapy*
Humans ; Mutation ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins ; Proto-Oncogene Proteins B-raf ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Alzheimer's target still viable but untested.
Autorzy:
Ashe KH; Department of Neurology, N. Bud Grossman Center for Memory Research and Care, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Aug 26; Vol. 377 (6609), pp. 935. Date of Electronic Publication: 2022 Aug 25.
Typ publikacji:
Letter; Comment
MeSH Terms:
Alzheimer Disease*/drug therapy
Amyloid beta-Peptides*/metabolism
Molecular Targeted Therapy*
Humans
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 19069

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz